Media

Our nuclear magnetic resonance (NMR) capability delivers enhanced molecular insight, accelerates analysis and strengthens quality control across pharmaceutical development and manufacturing.

We delivered record Q1 sales, reflecting the strength and diversity of our business portfolio.

SGS announces today that 61.35% of the dividend for the financial year 2025 was elected to be paid in the form of new SGS shares, while the remaining 38.65% will be paid out in cash.

SGS is pleased to announce that it has been included in the newly launched SPI^® ESG 25 Index, introduced by SIX, the Swiss stock exchange operator.

Expanded PFAS testing suite covering 73 compounds, delivering more accurate, future-ready analysis beyond standard methods.

Understanding the new SQF edition and what it means for your business.

All the resolutions proposed by the Board of Directors were approved at the Annual General Meeting in Zurich.

CEO Géraldine Picaud speaks with CNBC about our record financial performance in 2025 and the strong execution of Strategy 27.

SGS is pleased to announce that Moody’s has affirmed its A3 long-term issuer credit rating of the company and upgraded its credit outlook to stable from negative.